Nathan Brown Frsc
About Nathan Brown Frsc
Nathan Brown Frsc is the Head of Chemoinformatics at BenevolentAI and Chairperson of The UK-QSAR & Chemoinformatics Group, with extensive experience in computational chemistry and drug discovery.
Current Roles and Responsibilities
Nathan Brown Frsc is the Head of Chemoinformatics at BenevolentAI in London, United Kingdom, where he leads the application of computational techniques to drug discovery. He also serves as the Chairperson of The UK-QSAR & Chemoinformatics Group. In addition, he is on the International Advisory Board of ChemMedChem and the Supervisory Board of Molomics in Catalonia, Spain. Furthermore, he is a member of the Executive Committee for the Royal Society of Chemistry Chemical Information and Computer Applications Group and a Committee Member at The UK-QSAR & Chemoinformatics Group.
Education and Academic Background
Nathan Brown earned his Bachelor of Science degree from Robert Gordon University, completing his studies from 1995 to 1999. He then pursued a Doctor of Philosophy at The University of Sheffield, where he conducted his doctoral research from 1999 to 2002. His academic training laid the foundation for a career in chemoinformatics and computational chemistry, providing a strong basis for his work in drug discovery and medicinal chemistry.
Professional Experience and Contributions
During his career, Nathan Brown has held numerous influential positions. He was the Head of in Silico Medicinal Chemistry at The Institute of Cancer Research from 2007 to 2017. Prior to that, he worked as a Presidential Research Fellow at Novartis from 2004 to 2007 in Switzerland and as a Marie Curie Research Fellow at Avantium from 2002 to 2004 in the Netherlands. His extensive experience includes significant contributions to both academic and industrial research environments. He has international work experience, having held positions in the United Kingdom, Germany, Switzerland, and the Netherlands.
Authorship and Editorial Work
Nathan Brown has a history of contributing to scientific literature through various authorship and editorial roles. He authored 'Artificial Intelligence in Drug Discovery,' published by the Royal Society of Chemistry. He has also served as a book editor for Wiley VCH from 2011 to 2013 and authored a book for the Royal Society of Chemistry from 2014 to 2015. His published research includes work on machine learning applications in drug discovery, AI for COVID-19 treatment, and the use of deep neural networks for chemical syntheses.
Research and Scientific Publications
Nathan Brown has made substantial contributions to the field of chemoinformatics and computational chemistry through his research. His work includes developing AI models for molecular activity prediction and drug repurposing, notably for diseases like COVID-19. His publications appear in prestigious journals such as Nature, The Lancet, and the Journal of Chemical Information and Modeling. His expertise extends to the use of deep neural networks and symbolic AI in drug discovery, demonstrating a strong background in computational approaches to medicinal chemistry.